These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32891936)

  • 1. Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy.
    Ng SSW; Jang GH; Kurland IJ; Qiu Y; Guha C; Dawson LA
    EBioMedicine; 2020 Sep; 59():102973. PubMed ID: 32891936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
    Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
    Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
    Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma.
    Jun BG; Kim YD; Cheon GJ; Kim ES; Jwa E; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Lee SH; Kim HS
    Korean J Intern Med; 2018 Nov; 33(6):1093-1102. PubMed ID: 28844122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma.
    Moore A; Cohen-Naftaly M; Tobar A; Kundel Y; Benjaminov O; Braun M; Issachar A; Mor E; Sarfaty M; Bragilovski D; Hur RB; Gordon N; Stemmer SM; Allen AM
    Radiat Oncol; 2017 Oct; 12(1):163. PubMed ID: 29052532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
    J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.
    Liu HY; Lee YD; Sridharan S; Choong ES; Le H; Wang W; Khor R; Chu J; Oar A; Mott R; Smart J; Jenkins T; Anderson N; Cross S; Loo KF; Wigg A; Stuart K; Pryor D
    J Med Imaging Radiat Oncol; 2021 Jun; 65(3):365-373. PubMed ID: 33890425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.
    Nabavizadeh N; Waller JG; Fain R; Chen Y; Degnin CR; Elliott DA; Mullins BT; Patel IA; Dyer BA; Fakhoury K; Naugler WE; Farsad K; Tanyi JA; Fuss M; Thomas CR; Hung AY
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):577-585. PubMed ID: 29413273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy.
    Gkika E; Bettinger D; Krafft L; Schultheiss M; Neeff HP; Maruschke L; Schulenburg M; Adebahr S; Kirste S; Nestle U; Thimme R; Grosu AL; Brunner TB
    Strahlenther Onkol; 2018 May; 194(5):403-413. PubMed ID: 29322205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma.
    Ferrarini A; Di Poto C; He S; Tu C; Varghese RS; Kara Balla A; Jayatilake M; Li Z; Ghaffari K; Fan Z; Sherif ZA; Kumar D; Kroemer A; Tadesse MG; Ressom HW
    J Proteome Res; 2019 Aug; 18(8):3067-3076. PubMed ID: 31188000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
    Velec M; Haddad CR; Craig T; Wang L; Lindsay P; Brierley J; Brade A; Ringash J; Wong R; Kim J; Dawson LA
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):939-946. PubMed ID: 28333016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
    Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
    Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling.
    Patterson AD; Maurhofer O; Beyoglu D; Lanz C; Krausz KW; Pabst T; Gonzalez FJ; Dufour JF; Idle JR
    Cancer Res; 2011 Nov; 71(21):6590-600. PubMed ID: 21900402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS.
    Baniasadi H; Gowda GA; Gu H; Zeng A; Zhuang S; Skill N; Maluccio M; Raftery D
    Electrophoresis; 2013 Oct; 34(19):2910-7. PubMed ID: 23856972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.
    Jackson WC; Suresh K; Maurino C; Feng M; Cuneo KC; Ten Haken RK; Lawrence TS; Schipper MJ; Owen D
    Radiother Oncol; 2019 Dec; 141():101-107. PubMed ID: 31431377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic Body Radiotherapy for Small Unresectable Hepatocellular Carcinomas.
    Yeung R; Beaton L; Rackley T; Weber B; Hamm J; Lee R; Camborde M; Pearson M; Duzenli C; Loewen SK; Liu M; Ma R; Schellenberg D
    Clin Oncol (R Coll Radiol); 2019 Jun; 31(6):365-373. PubMed ID: 30792051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.
    Liu HY; Lee Y; McLean K; Leggett D; Hodgkinson P; Fawcett J; Mott R; Stuart K; Pryor D
    Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e194-e202. PubMed ID: 32345457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up.
    Mendiratta-Lala M; Masch W; Shankar PR; Hartman HE; Davenport MS; Schipper MJ; Maurino C; Cuneo KC; Lawrence TS; Owen D
    Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):169-179. PubMed ID: 30213751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.